Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

@article{Nvoa2006PlasmaLO,
  title={Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.},
  author={Sonia Rodr{\'i}guez N{\'o}voa and Pablo Barreiro and Ana Cecilia P{\'e}rez Rend{\'o}n and Ana Barrios and Ang{\'e}lica Corral and Inmaculada Jim{\'e}nez-N{\'a}cher and J. Gonz{\'a}lez-lahoz and Vicente Soriano},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2006},
  volume={42 2},
  pages={
          291-5
        }
}
The 3435C-->T polymorphism at the multidrug resistance gene 1 (MDR1) was examined in 74 patients with human immunodeficiency virus who initiated atazanavir therapy. The MDR1 genotype distribution at position 3435 was 28% CC, 45% CT, and 27% TT. Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations. 

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-3 of 3 extracted citations

Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2010
View 4 Excerpts
Highly Influenced